Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-30

Study Completion Date

2021-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, investigators will determine whether the early addition of HT-CCP to standard treatment improves the clinical outcome (as assessed by the Modified WHO Ordinal Scale) of patients with COVID-19 who are hospitalized but not yet in moderate or severe ARDS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Convalescent Plasma vs. Standard Plasma for COVID-19

NCT04344535

COVID

TERMINATED PHASE1/PHASE2

Convalescent Plasma in the Treatment of COVID 19

NCT04343261

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) COVID Coronavirus

COMPLETED PHASE2

Plasma Therapy of COVID-19 in Severely Ill Patients

NCT04359810

SARS-CoV-2 Infection

COMPLETED PHASE2

Efficacy of Convalescent Plasma Therapy in Patients With COVID-19

NCT04425915

COVID

COMPLETED PHASE3

Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients

NCT04354831

COVID-19

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Investigators are doing this research to learn more about high-titer COVID-19 convalescent plasma (HT-CCP) transfusion as a possible treatment for people who have COVID-19, the coronavirus infection. "HT-CCP" is plasma that contains a high amount of antibodies that were made to fight off COVID-19 because it is donated by another person who has also been infected with coronavirus but has recovered, so their immune system has had enough time to make these antibodies. This study is being done to determine whether HT-CCP will help people with COVID-19 recover from their infection more quickly and lower their risk of having to go on a ventilator or reduce the time they need to stay on a ventilator. It is not yet known whether HT-CCP helps people with COVID-19, which is why the study needs to be randomized, meaning some subjects will be randomly selected to receive HT-CCP while others will be randomly selected to receive FFP.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID Infectious Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A

Two units of apheresis HT-CCP, collected from the same donor whenever possible, will be administered sequentially over no greater than a 24-hour period to participants randomized to Arm A. Each unit of HT-CCP will be approximately 250 mL, for a total transfused volume of approximately 500 mL.

Group Type EXPERIMENTAL

High-Titer COVID-19 Convalescent Plasma (HT-CCP)

Intervention Type BIOLOGICAL

250mL HT-CCP x2 doses given sequentially.

Arm B

Two units of FFP or FP24 (each 200-275 mL, approximately 500 mL total) will be administered sequentially to participants randomized to Arm B. (FFP/FP24 unit volumes vary more than apheresis plasma units. Two FFP/FP24 units that are approximately 250 mL apiece will be provided.)

Group Type PLACEBO_COMPARATOR

Standard Plasma (FFP)

Intervention Type BIOLOGICAL

250mL FFP or FP24 x2 doses given sequentially.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

High-Titer COVID-19 Convalescent Plasma (HT-CCP)

250mL HT-CCP x2 doses given sequentially.

Intervention Type BIOLOGICAL

Standard Plasma (FFP)

250mL FFP or FP24 x2 doses given sequentially.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age \>1 year.
2. Active COVID-19 infection confirmed by positive SARS-CoV-2 PCR.
3. Meets institutional criteria for admission to hospital for COVID-19.
4. Admitted to ICU or non-ICU floor within 5 days of enrollment.
5. PaO2/FiO2 \>200 mmHg if intubated.
6. Patient or LAR able to provide informed consent.

Exclusion Criteria

1. Previous treatment with convalescent plasma for COVID-19.
2. Current use of investigational antiviral therapy targeting SARS-CoV-2.
3. History of anaphylactic transfusion reaction.
4. Clinical diagnosis of acute decompensated heart failure.
5. Objection to blood transfusion.

Minimum Eligible Age

12 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No